Category - Developments

Developments

Adocia and Tonghua Dongbao in insulin strategic alliance in China

Adocia (Euronext Paris:FR0011184241 – ADOC) and Tonghua Dongbao Pharmaceuticals (Shanghai Stock Exchange 600867) announced a strategic partnership, giving Tonghua exclusive development and commercialization rights in...

April 26, 2018

Developments

Theratechnologies to seek approval of Trogarzo in Europe

Theratechnologies (TSX:TH) plans to seek regulatory approval from the European Medicines Agency (EMA) for Trogarzo using efficacy and safety data from clinical trials submitted to the FDA. “Based on our discussions, we...

April 24, 2018

Developments

CellAegis inks first distribution deal for autoRIC in Europe

Closely-held CellAegis Devices entered into a definitive agreement with Cardiologic, for the marketing and distribution of its autoRIC device in the UK and Ireland. “This marks the first distribution agreement for the...

April 24, 2018

Developments

Oramed starts 90-day pivotal dose-ranging study for oral insulin

Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) has begun screening patients in its 90-day dose-ranging pivotal Phase 2b HbA1c clinical study of its oral insulin capsule, ORMD-0801. A statistically significant improvement in...

April 23, 2018

Developments

Titan Pharma’s Probuphine implant for long-term maintenance treatment of opioid dependence approved by Health Canada

Health Canada has approved the sale of Probuphine, a subdermal implant developed by Titan Pharmaceuticals (NASDAQ:TTNP), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of...

April 20, 2018

Developments

FDA committee approves GW Pharma cannabidiol for seizures

The Peripheral and Central Nervous System Drugs Advisory Committee of the FDA unanimously recommended supporting the approval of the NDA from GW Pharmaceuticals (NASDAQ:GWPH) and its U.S. subsidiary Greenwich...

April 19, 2018

Developments

FDA approves Angel Medical implantable cardiac monitor

Closely-held Angel Medical Systems has received FDA premarket approval for the AngelMed Guardian System, an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The...

April 18, 2018

Developments

Novocure posts positive mesothelioma data; to file for FDA exemption

Novocure (NASDAQ:NVCR) reported positive top-line results from its STELLAR Phase 2 pilot trial in mesothelioma. The data demonstrate clinically meaningful improvements in overall survival and progression free survival...

April 17, 2018

Developments

Eiger BioPharma presents additional lonafarnib data in HDV

Eiger BioPharmaceuticals (NASDAQ:EIGR) presented additional positive lonafarnib (LNF) data from the LOWR hepatitis delta virus (HDV) program at the International Liver Congress 2018 in Paris. A sub-analysis of the LOWR...

April 17, 2018

Developments

Profound Medical Q2 Top Pick at Paradigm Capital

Paradigm Capital has made Profound Medical (TSXV:PRN; OTCQX:PRFMF) its second quarter Top Pick, saying the next three-to-four months are expected to be an accretive time for Profound. Analyst Rahul Sarugaser writes that...

April 12, 2018

Category - Developments

Adocia and Tonghua Dongbao in insulin strategic alliance in China

Theratechnologies to seek approval of Trogarzo in Europe

CellAegis inks first distribution deal for autoRIC in Europe

Oramed starts 90-day pivotal dose-ranging study for oral insulin

Titan Pharma’s Probuphine implant for long-term maintenance treatment of opioid dependence approved by Health Canada

FDA committee approves GW Pharma cannabidiol for seizures

FDA approves Angel Medical implantable cardiac monitor

Novocure posts positive mesothelioma data; to file for FDA exemption

Eiger BioPharma presents additional lonafarnib data in HDV

Profound Medical Q2 Top Pick at Paradigm Capital

General

More